ILD - Does not meet expectations










































The pediatric indication was an extreme long shot anyway with small financial profit if it happened. PDE4 will be another blockbuster so ILD will continue to be a key player for BI.
 












Entire ILD division is a complete flop!! Incompetent nincompoops!
There are actually some good people in ILD. There have just been market factors that have consequences. Losing a branded competitor decreases noise about lung disease. Generic competition didn’t help. And ultimately Al leaving has negative impact on the team culture. OFEV was never meant to be a $2+ billion drug. The brand got lucky and now expectations are high and unreasonable.